MRI示踪的纳米酶用于级联反应增强的免疫治疗

隋美菊; 张磊; 王瑞芳; 骆盈盈; 李莎; 丘茂松; 徐秋怡; 陈代钦; 陈世桢; 周欣

doi:10.11938/cjmr20253149

波谱学杂志 >

2025 , Vol. 42 >Issue 3: 231 - 248

DOI: https://doi.org/10.11938/cjmr20253149

研究论文

MRI示踪的纳米酶用于级联反应增强的免疫治疗

隋美菊 ,
张磊 ,
王瑞芳 ,
骆盈盈 ,
李莎 ,
丘茂松 ,
徐秋怡 ,
陈代钦 ,
陈世桢 ,
周欣

展开

1.中国科学院精密测量科学与技术创新研究院，磁共振波谱与成像全国重点实验室，武汉磁共振中心，湖北武汉 430071
2.中国科学院大学，北京 100049
3.海南大学，生物医学工程学院，海南三亚 572019

收稿日期: 2025-03-14

网络出版日期: 2025-05-06

基金资助

中国科学院战略重点研究项目(XDB0540000);国家自然科学基金项目(22327901);国家自然科学基金项目(U21A20392);国家自然科学基金项目(82127802);湖北省自然科学基金(2024AFB261);中国科学院青年跨学科团队(JCTD-2022-13);中国科学院青年创新促进会;中国科学院青年拔尖人才培养计划

收起

MRI-traceable Nanoenzyme for Cascade Catalysis-enhanced Immunotherapy

SUI Meiju ,
ZHANG Lei ,
WANG Ruifang ,
LUO Yingying ,
LI Sha ,
QIU Maosong ,
XU Qiuyi ,
CHEN Daiqin ,
CHEN Shizhen ,
ZHOU Xin

Expand

1. State Key Laboratory of Magnetic Resonance Spectroscopy and Imaging, National Center for Magnetic Resonance in Wuhan, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan 430071, China
2. University of Chinese Academy of Sciences, Beijing 100049, China
3. School of Biomedical Engineering, Hainan University, Sanya 572019, China

Received date: 2025-03-14

Online published: 2025-05-06

Fold

摘要

免疫抑制性肿瘤微环境（ITME）对抗肿瘤免疫治疗构成了重大障碍．为应对这一挑战，本研究基于Mn²⁺和内源性血红素制备了一种新型纳米酶，其具有多重类酶催化活性，可有效逆转ITME并激活抗肿瘤免疫应答，从而协同增强免疫检查点抑制剂（Immune checkpoint inhibitor，ICI）αPD-L1对肿瘤生长和转移的抑制作用．同时，该纳米酶兼具磁共振成像功能，可实现对肿瘤及纳米酶分布的可视化追踪．

关键词： 磁共振成像; 免疫治疗; 血红素; 铁死亡; 光热治疗

本文引用格式

隋美菊 , 张磊 , 王瑞芳 , 骆盈盈 , 李莎 , 丘茂松 , 徐秋怡 , 陈代钦 , 陈世桢 , 周欣 . MRI示踪的纳米酶用于级联反应增强的免疫治疗[J]. 波谱学杂志, 2025 , 42(3) : 231 -248 . DOI: 10.11938/cjmr20253149

Abstract

The immunosuppressive tumor microenvironment (ITME) poses a significant challenge to anti-tumor immunotherapy. Our research develops a novel nanoenzyme based on Mn²⁺ and endogenous hemin. The nanozyme possesses superior multi-enzymatic activities, which could significantly reverse the ITME and trigger a vigorous anti-tumor immune response, thereby inhibiting both tumor growth and metastasis when used in conjunction with immune checkpoint inhibitor (ICI), αPD-L1. Moreover, it functions as a magnetic resonance imaging (MRI) contrast agent for the visualization of tumors and the trace of nanoenzyme.

Key words： magnetic resonance imaging (MRI); immunotherapy; hemin; ferroptosis; photothermal therapy

参考文献

[1]	ANSELL S M, LESOKHIN A M, BORRELLO I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J]. N Engl J Med, 2014, 372(4): 311-319.
[2]	HODI F S, O'DAY S J, MCDERMOTT D F, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723.
[3]	MELLMAN I, COUKOS G, DRANOFF G. Cancer immunotherapy comes of age[J]. Nature, 2011, 480(7378): 480-489.
[4]	VANNEMAN M, DRANOFF G. Combining immunotherapy and targeted therapies in cancer treatment[J]. Nat Rev Cancer, 2012, 12(4): 237-251.
[5]	ALI S, KJEKEN R, NIEDERLAENDER C, et al. The European medicines agency review of kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma[J]. Oncologist, 2020, 25(2): e321-e327.
[6]	SHI Y, LAMMERS T. Combining nanomedicine and immunotherapy[J]. Acc Chem Res, 2019, 52(6): 1543-1554.
[7]	MUSETTI S, HUANG L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy[J]. ACS Nano, 2018, 12(12): 11740-11755.
[8]	LARKIN J, CHIARION-SILENI V, GONZALEZ R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1): 23-34.
[9]	FAN W P, YUNG B, HUANG P, et al. Nanotechnology for multimodal synergistic cancer therapy[J]. Chem Rev, 2017, 117(22): 13566-13638.
[10]	CHENG L, JIANG D, KAMKAEW A, et al. Renal-clearable PEGylated porphyrin nanoparticles for image-guided photodynamic cancer therapy[J]. Adv Funct Mater, 2017, 27(34): 1702928.
[11]	LI B, XIE X, CHEN Z, et al. Tumor inhibition achieved by targeting and regulating multiple key elements in EGFR signaling pathway using a self-assembled nanoprodrug[J]. Adv Funct Mater, 2018, 28(22): 1800692.
[12]	LI Y, XU N, ZHU W, et al. Nanoscale melittin@zeolitic imidazolate frameworks for enhanced anticancer activity and mechanism analysis[J]. ACS Appl Mater Interfaces, 2018, 10(27): 22974-22984.
[13]	GONG Y, WANG P, CAO R, et al. Exudate absorbing and antimicrobial hydrogel integrated with multifunctional curcumin-loaded magnesium polyphenol network for facilitating burn wound healing[J]. ACS Nano, 2023, 17(22): 22355-22370.
[14]	REN Z, SUN S, SUN R, et al. A metal-polyphenol-coordinated nanomedicine for synergistic cascade cancer chemotherapy and chemodynamic therapy[J]. Adv Mater, 2020, 32(6): e1906024.
[15]	YANG W, DENG C, SHI X, et al. Structural and molecular fusion MRI nanoprobe for differential diagnosis of malignant tumors and follow-up chemodynamic therapy[J]. ACS Nano, 2023, 17(4): 4009-4022.
[16]	ZHANG Z, LI B, XIE L, et al. Metal-phenolic network-enabled lactic acid consumption reverses immunosuppressive tumor microenvironment for sonodynamic therapy[J]. ACS Nano, 2021, 15(10): 16934-16945.
[17]	XIONG Y X, WANG W, DENG Q Y, et al. Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA mechanics damage repair pathways and modulating tumor[J]. Nano Today, 2023, 49: 101767.
[18]	ZHANG Y, TANG S Q, FENG X Y, et al. Tumor-targeting gene-photothermal synergistic therapies based on multifunctional polydopamine nanoparticles[J]. Chem Eng J, 2023, 457: 141315.
[19]	ZHOU M X, WANG J X, PAN J X, et al. Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy[J]. Nat Commun, 2023, 14(1): 3593.
[20]	WANG B J, WANG T, JIANG T Z, et al. Circulating immunotherapy strategy based on pyroptosis and STING pathway: Mn-loaded paclitaxel prodrug nanoplatform against tumor progression and metastasis[J]. Biomaterials, 2024, 306: 122472.
[21]	CHEN C, SHEN X T, SHI S L, et al. Biomimetic Fe³⁺ metal-phenolic networks enable DNAzyme and Cas9 RNP delivery for synergistic tumor ferroptosis-immunotherapy[J]. Chem Eng J, 2024, 499: 156050.
[22]	INTAKHAD J, VACHIRAARUNWONG A, WONGPOOMCHAI R, et al. Ferric-tannic nanoparticles inhibit early-stage hepatocarcinogenesis by activating tumor immune responses in rats[J]. Adv Ther, 2024, 7(12): 2400348.
[23]	CHEN H Q, LIU L L, MA A Q, et al. Noninvasively immunogenic sonodynamic therapy with manganese protoporphyrin liposomes against triple-negative breast cancer[J]. Biomaterials, 2021, 269: 120639.
[24]	LI Z F, WANG C M, DAI C, et al. Engineering dual catalytic nanomedicine for autophagy-augmented and ferroptosis-involved cancer nanotherapy[J]. Biomaterials, 2022, 287: 121668.
[25]	LIU J J, LIU S W, WU Y C, et al. Curcumin doped zeolitic imidazolate framework nanoplatforms as multifunctional nanocarriers for tumor chemo/immunotherapy[J]. Biomater Sci, 2022, 10(9): 2384-2393.
[26]	XIA Y X, JI X R, LI Q R. Research progress on application of immune checkpoint inhibitors combined with curcumin in tumor treatment[J]. Journal of Medical Forum, 2025, 46(7): 780-784.
	夏雨轩, 纪翛然, 李倩如. 免疫检查点抑制剂联合姜黄素在肿瘤治疗中的应用研究进展[J]. 医药论坛杂志, 2025, 46(7): 780-784.
[27]	YAN H, HUANG S. Anti-tumor effect of curcumin on human colorectal cancer SW-620 cells[J]. Journal of Tianjin Medical University, 2024, 30(6): 479-484.
	阎晗, 黄珊. 姜黄素对人结直肠癌SW-620细胞抗肿瘤效果的研究[J]. 天津医科大学学报, 2024, 30(6): 479-484.
[28]	CHEN L, LI Y Y, GAO F Y, et al. Study on the effect of dihydroartemisinin on ferroptosis in ovarian cancer cells by regulating SLC7A11/GPX4 signaling pathway[J]. Journal of Chinese Medicinal Materials, 2024, (12): 3103-3107.
	陈露, 李由由, 杲飞莹, 等. 双氢青蒿素通过调节SLC7A11/GPX4信号通路诱导卵巢癌细胞铁死亡[J]. 中药材, 2024, (12): 3103-3107.
[29]	XU J R, JIA F J, CHEN J L, et al. Research of dihydroartemisinin on anti-colorectal cancer by regulating MAPK/PI3K/Akt signaling pathway[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine, 2024, 38(2): 83-92.
	徐嘉若, 贾丰菁, 陈佳靓, 等. 双氢青蒿素通过调控MAPK/PI3K/Akt信号通路抗结直肠癌作用研究[J]. 上海中医药大学学报, 2024, 38(2): 83-92.
[30]	HU X X, ZHAO Y, WANG Y, et al. Study on the nano-drug delivery system and anti-tumor mechanism of artemisinin and its derivatives[J]. Chemical Reagents, 2024, 46(7): 11-19.
	胡晓娴, 赵雨, 王赟, 等. 青蒿素及其衍生物纳米药物递送系统和抗肿瘤机制研究[J]. 化学试剂, 2024, 46(7): 11-19.
[31]	GUO Y J, DENG L, LI J, et al. Hemin-graphene hybrid nanosheets with intrinsic peroxidase-like activity for label-free colorimetric detection of single-nucleotide polymorphism[J]. ACS Nano, 2011, 5(2): 1282-1290.
[32]	GOLUB E, FREEMAN R, WILLNER I. A hemin/G-quadruplex acts as an NADH oxidase and NADH peroxidase mimicking DNAzyme[J]. Angew Chem Int Ed Engl, 2011, 50(49): 11710-11714.
[33]	YANG Y, ZHU W J, FENG L Z, et al. G-quadruplex-based nanoscale coordination polymers to modulate tumor hypoxia and achieve nuclear-targeted drug delivery for enhanced photodynamic therapy[J]. Nano Lett, 2018, 18(11): 6867-6875.
[34]	LI K, XU K, HE Y, et al. Functionalized tumor-targeting nanosheets exhibiting Fe(II) overloading and GSH consumption for ferroptosis activation in liver tumor[J]. Small, 2021, 17(40): e2102046.
[35]	LI X C, ZHANG X, SONG L, et al. Nanozyme as tumor energy homeostasis disruptor to augment cascade catalytic therapy[J]. ACS Nano, 2024, 18(51): 34656-34670.
[36]	CHAO F R, CAO C L, XU Y, et al. Sprayable hydrogel for pH-responsive nanozyme-derived bacteria-infected wound healing[J]. ACS Appl Mater Interfaces, 2025, 17(4): 5921-5932.
[37]	ELIA I, HAIGIS M C. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism[J]. Nat Metab, 2021, 3(1): 21-32.
[38]	JIN M Z, JIN W L. The updated landscape of tumor microenvironment and drug repurposing[J]. Signal Transduct Target Ther, 2020, 5(1): 166.
[39]	FAN Y, CHEN L, ZHENG Y, et al. Nanoparticle-based activatable MRI probes for disease imaging and monitoring[J]. Chem Biomed Imaging, 2023, 1(3): 192-204.
[40]	WU F, DU Y Q, YANG J N, et al. Peroxidase-like active nanomedicine with dual glutathione depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death[J]. ACS Nano, 2022, 16(3): 3647-3663.
[41]	YANG B C, DAI Z C, ZHANG G R, et al. Ultrasmall ternary FePtMn nanocrystals with acidity-triggered dual-Ions release and hypoxia relief for multimodal synergistic chemodynamic/photodynamic/photothermal cancer therapy[J]. Adv Healthc Mater, 2020, 9(21): e1901634.
[42]	ZHAO Z Y, DONG S M, LIU Y, et al. Tumor microenvironment-activable manganese-boosted catalytic immunotherapy combined with PD-1 checkpoint blockade[J]. ACS Nano, 2022, 16(12): 20400-20418.
[43]	NEMETH T, PALLIER A, ?ELIK ?, et al. Water-soluble Mn(III)-porphyrins with high relaxivity and photosensitization[J]. Chem Biomed Imaging, 2025, 3(1): 5-14.
[44]	ZENG Q B, GUO Q N, LUO Q, et al. Manganese-based contrast agents for MRI[J]. Chin J Magn Reson Imaging, 2014, 5(4): 315-320.
	曾庆斌, 郭茜旎, 罗晴, 等. 锰对比剂在MRI中的应用[J]. 磁共振成像, 2014, 5 (4): 315-320.
[45]	ZHANG H X, YANG S P. Research progress of manganese(II)-based contrast agents in magnetic resonance imaging[J]. Journal of Shanghai Normal University (Natural Sciences), 2025, 54(1): 53-61.
	张何仙, 杨仕平. 锰(II)基造影剂在磁共振成像中的研究进展[J]. 上海师范大学学报(自然科学版), 2025, 54(1): 53-61.
[46]	CHEN L, DING C P, CHAI K J, et al. Nanohole-array induced metallic molybdenum selenide nanozyme for photoenhanced tumor-specific therapy[J]. ACS Nano, 2023, 17(18): 18148-18163.
[47]	ZHU Y L, ZHAO R X, FENG L, et al. Dual nanozyme-driven PtSn bimetallic nanoclusters for metal-enhanced tumor photothermal and catalytic therapy[J]. ACS Nano, 2023, 17(7): 6833-6848.
[48]	PENG L, ZHAO A G, LI R K, et al. Self-propelled in situ polymerized nanoparticles activating the STING pathway for enhanced bladder cancer immunotherapy[J]. Adv Sci, 2025, 12: 2502750.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献